Filter by content type
Filter by year
Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
May 13, 2020 - … Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … Annual Meeting … Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
April 27, 2020 - … Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in … Virtual Annual Meeting … Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in …
Vaccinex Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 9, 2020 - … 03/09/20 Earnings On-track to report topline data from CLASSICAL-Lung and SIGNAL clinical trials this year Announces expansion … Clinical Updates: Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung clinical trial . Near topline data in the …
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 - … Earnings Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to … Accomplishments: Presented updated interim data from the CLASSICAL-Lung Phase 1b/2 study of the company’s lead product … . Pepinemab Clinical Updates: Non-Small Cell Lung Cancer - CLASSICAL-Lung Clinical Trial . The company’s ongoing …
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 14, 2020 - … will be released by early October 2020 . Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung clinical trial . The CLASSICAL-Lung study is evaluating pepinemab in combination …
Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs
March 31, 2020 - … Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial … and will provide further updates as warranted. CLASSICAL-Lung. The CLASSICAL-Lung study is evaluating pepinemab in combination …
Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium
February 6, 2020 - … in a Phase 1b/2 study in patients with non-small cell lung cancer (NSCLC). Interim results that we recently … the event. Visit the website at www.vaccinex.com . About CLASSICAL – Lung Vaccinex is currently evaluating its novel … , Darmstadt, Germany . The clinical trial, short-named “CLASSICAL – Lung”, is a multi-center, open-label study …
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 13, 2020 - … and loss of brain metabolic activity. Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung C linical T rial . The recently completed CLASSICAL-Lung study evaluated pepinemab in combination with …
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab
September 22, 2020 - … with avelumab checkpoint inhibitor in Non-Small Cell Lung Cancer . A new collaboration with Merck to test the … with currently active clinical trials in Non-Small Cell Lung Cancer , Huntington’s and Alzheimer’s disease and a … with avelumab checkpoint inhibitor in Non-Small Cell Lung Cancer . A new collaboration with Merck to test the …
Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
June 9, 2020 - … clinical trials in Huntington’s disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . … clinical trials in Huntington’s disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . … clinical trials in Huntington’s disease and Non-Small Cell Lung Cancer . Vaccinex is based in Rochester, New York . …